Home Cart Sign in  
Chemical Structure| 912999-49-6 Chemical Structure| 912999-49-6

Structure of Onalespib
CAS No.: 912999-49-6

Chemical Structure| 912999-49-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity.

Synonyms: AT13387

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Onalespib

CAS No. :912999-49-6
Formula : C24H31N3O3
M.W : 409.52
SMILES Code : O=C(C1=CC(C(C)C)=C(O)C=C1O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2
Synonyms :
AT13387
MDL No. :MFCD18633198
InChI Key :IFRGXKKQHBVPCQ-UHFFFAOYSA-N
Pubchem ID :11955716

Safety of Onalespib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Onalespib

DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01246102 Solid Tumors|Breast Cancer PHASE1 COMPLETED 2017-10-27 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT02572453 Recurrent Anaplastic Large Cel... More >>l Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma Less << PHASE2 TERMINATED 2021-03-18 Los Angeles County-USC Medical... More >> Center, Los Angeles, California, 90033, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, 92663, United States|Keck Medical Center of USC Pasadena, Pasadena, California, 91105, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, 68123, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, 68118, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08903, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|Parkland Memorial Hospital, Dallas, Texas, 75235, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.21mL

2.44mL

1.22mL

24.42mL

4.88mL

2.44mL

References

 

Historical Records

Categories